Research progress in PC lags far behind other cancers, and early clinical trials of immune therapy with anti-CTLA-4 and anti-PD-L1 antibodies have shown poor efficacy in advanced PC patients [126]. The gene discussed is CTLA4; the disease is pachyonychia congenita.